Nephrology
Clinical discussions on kidney disease management, dialysis, transplantation, and electrolyte disorders.
Recent Discussions
Are there any special considerations you take with ESA use in hospitalized patients with ESKD who undergo stem cell transplantation?
There really are no guidelines for the use of ESAs in this population. Generally, these patients receive PRBC support for severe and/or symptomatic anemia. We do not prescribe ESAs int this setting because we suspect that the response will be suboptimal given the inflammatory state of these patients...
For outpatients undergoing a kidney biopsy, do you routinely recommend an overnight admission for continued hemoglobin monitoring?
If I perform an uneventful kidney biopsy in the morning on a patient with well-controlled BP and normal hemoglobin, I can observe the patient all day. If vitals are stable and the repeat hemoglobin at 8 hours is stable, I would discharge the patient. However, if I did the biopsy later in the day or ...
Under what circumstances would you consider a bone biopsy in the workup of renal osteodystrophy?
I am always in favor of doing more diagnostic tests. The problem is that it is often practically hard to get a bone biopsy. I would suggest it anytime there a question of what is happening with the bone disease.
How long would you wait before performing a kidney biopsy in a patient with nephrotic range proteinuria, a negative PLA2R antibody, a negative anti-THSD7A antibody, and stable renal function who recently started treatment a week ago with a DOAC for a pulmonary embolism?
Since the renal function is stable, and holding the DOAC carries significant risk, I would wait at least 3 months, and if the kidney function is still stable then, possible 6 months before the kidney biopsy.
How do you approach managing patients with recurrent nephrolithiasis who have low supersaturation profiles due to polyuria and stable stone disease on imaging but do have persistent urinary abnormalities such as hyperoxaluria, hypercalciuria, and hypocitraturia?
If the stone disease is metabolically stable (no change in stone size or increase in number by serial CT imaging), I do not treat urinary chemical abnormalities. Presumably these patients have high levels of urinary inhibitors of crystallization. I encouraged them to continue their successful stone ...
Would you obtain an abdominal non-contrast CT study for further routine evaluation of stone burden in a patient with recurrent nephrolithiasis who recently completed an abdominal iodinated contrast CT study for non-stone purposes?
Often, there is no pre-contrast imaging, and stones cannot be counted well once contrast enters the kidneys. So, unless there was a pre-contrast phase, the contrast CT cannot be considered adequate for determining stone burden and new stone activity. So if either is at issue, I would obtain a non-co...
Would you add amiloride for patients with recurrent calcium nephrolithiasis who have hypercalciuria despite adherence to maximum dose thiazide, low sodium dietary intake, and low animal protein dietary intake?
Amiloride does not lower urine calcium on a chronic basis. In one set of experiments, acute loading lowered urine calcium, but the effect was very brief. I use amiloride to prevent potassium wasting from thiazides and on and off in primary hyperaldosteronism, but it will not lower urine calcium in t...
How do you advise your patients with recurrent nephrolithiasis to avoid consuming more than usual fluid volume on the day of a scheduled 24 hour urine stone risk study?
I tell them to collect on a day that represents their life as lived - how things are in general. I tell them not to show off. I tell them that if the day does not reflect their usual life, I will be misled and may make mistakes in how I treat them for stone prevention.
What is your recommended sequence of therapies for achieving optimal proteinuria reduction in IgA nephropathy, especially in light of the recent approvals of sparsentan, delayed-release budesonide, and iptacopan?
I am actually quite persistent with conservative therapies first - I push an ARB or ACE inhibitor in an effort to get the proteinuria under 1 gram per day, or ideally 0.75 gram per day. I favor stronger ARBs such as olmesartan or azilsartan over weaker ones such as losartan or valsartan, and really ...
Would you start a mineralocorticoid receptor antagonist or aprocitentan first in a patient with resistant hypertension and advanced CKD?
My cut offs for prescribing a new mineralocorticoid receptor antagonist are eGFR < 30 (for spironolactone and eplerenone) and eGFR < 25 (for finerenone). I will, however, continue these meds down to an eGFR of 15 if they have been taking them without a history of hyperkalemia, which is often the cas...